Navigation Links
PSA Can Predicts The Treatment Response In Advanced Prostate Cancer

A new study that has been conducted by researchers from the University of Michigan (U-M) medical school states that patients with lower PSA levels, //7 months after therapy lived longer.

According to a new multicentre study that has been conducted by the Southwest Oncology Group and led by researchers at the U-M Comprehensive Cancer Centre, that has been published in the August 20th issue of the Journal of Clinical Oncology, has explained that a test that is usually done to detect prostate cancer could also help doctors to know when the treatment is working. They further mentioned that the level of the prostate specific antigen, or PSA, in man after seven months of hormone therapy for advanced prostate cancer might foretell how long he would survive.

The study evaluated 1,345 men with prostate cancer that had spread to distant parts of the body. The men were treated with seven months of androgen deprivation therapy, a treatment designed to block the effects of hormones on the cancer. PSA levels were monitored throughout the treatment. The researchers found that men whose PSA dropped below 4.0 ng/ml had a quarter the risk of dying compared to those whose PSA was more than 4.0.

“Our analysis showed that a low or undetectable PSA after seven months of androgen deprivation therapy is a powerful predictor of risk of death in patients with new metastatic prostate cancer. This could allow oncologists to identify patients who are unlikely to do well with this treatment long before they develop clinical signs of treatment resistance,” says lead study author Maha Hussain, M.D., professor of internal medicine at the U-M Medical School.

The researchers found 69 percent of the men maintained a PSA level of less than 4.0 ng/ml after seven months of treatment and 43 percent had an undetectable level of PSA at that time. Patients whose PSA was higher than 4.0 at the end of seven months survived 13 months, while patients whose PSA drop ped below 4.0 but above 0.2 lived 44 months and those whose PSA was undetectable, below 0.2 ng/ml, lived 75 months.

The men in the study were enrolled in a Phase III SWOG trial in which they would receive additional treatment after the seven months of initial hormone therapy. That study seeks to accrue 1,512 men. The patient's PSA level before beginning treatment must be at least 5.0 ng/ml to qualify for the study.

A PSA test measures the level in the blood of prostate specific antigen, an enzyme produced by the prostate gland. It is generally used as an initial screening test to detect prostate cancer.

“What is attractive about using PSA to predict survival in metastatic prostate cancer is that it is an easily measurable factor. These findings could help patients avoid ineffective treatment and could help researchers design further trials,” Hussain says.

Source: EurekAlrt.
'"/>




Related medicine news :

1. Restricted Activity Predicts Disability
2. Fitness Level Predicts Stroke
3. Being Teased Predicts Poor Psychological Functioning in Youth With Cleft Lip
4. Model Predicts Colon Cancer Inheritable Genetic Defects
5. Formula Predicts Osteoporotic Fracture Risk
6. Computer Tool Predicts Effectiveness Of Microbicides
7. New Genetic Test Predicts Eye-Cancer Patients Futures
8. Technology Predicts Outcome of Child Heart Surgery
9. A Secret Dossier Predicts Major Changes At NHS, England
10. Activation of a Particular Brain Region Predicts Altruism: Study
11. New Test Predicts CLL’s Sensitivity to Experimental Drug
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2018)... ... August 15, 2018 , ... Trumpet ... BCBA-D, to associate editor of Behavior Analysis in Practice, one of the leading ... chief clinical standards and research officer for Trumpet, leading the company’s research clinical ...
(Date:8/14/2018)... ... August 14, 2018 , ... Health & hygiene ... , which is the largest study of brands based on emotions. In the U.S., ... the Top 10 for the health & hygiene industry were: Listerine, Nivea, Gillette, Colgate, ...
(Date:8/11/2018)... ... 2018 , ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon at Monarch ... outpost trip to deliver dental care in impoverished communities. Along with a team of ... his time to help deliver care to over 550 individuals in need. , This ...
(Date:8/11/2018)... ... August 11, 2018 , ... ... Stevie® Award in the Executive of the Year-Business category in The 15th Annual ... awards program. All individuals and organizations worldwide – public and private, for-profit and ...
(Date:8/9/2018)... ... August 09, 2018 , ... Striving ... Smart-pill bottle and mobile applications, DoseSmart announced today the availability of its ... medication management and medication adherence platform helps hospitals and health systems easily ...
Breaking Medicine News(10 mins):
(Date:8/14/2018)... TAMPA, Fla. (PRWEB) , ... August 14, 2018 ... ... nation’s largest faith-based health care systems, with nearly 50 hospital campuses and more ... name change, the health system will move to being one consumer-centric, connected and ...
(Date:8/14/2018)... ... August 14, 2018 , ... Reiter Affiliated Companies ... and hands-on educational program developed for students throughout California. , More ... or university, spent a minimum of 6 weeks of their summer with RAC ...
(Date:8/11/2018)... ROSEVILLE, Calif. (PRWEB) , ... August 10, 2018 , ... ... Roseville, CA traveled to Paraguay to deliver dental care in underserved communities surrounding its ... affiliated colleagues and support staff, Dr. Herman volunteered his time to help deliver care ...
Breaking Medicine Technology: